Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) — Medica

Initial criteria

• age ≥ 18 years
• For relapsing forms of multiple sclerosis: patient has a relapsing form of multiple sclerosis (examples: clinically isolated syndrome, relapsing remitting disease, active secondary progressive disease)
• Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis

Reauthorization criteria

• age ≥ 18 years
• Patient has a relapsing form of multiple sclerosis (examples: clinically isolated syndrome, relapsing remitting disease, active secondary progressive disease)
• Patient experienced a beneficial clinical response when assessed by at least one objective measure (e.g., stabilization or reduced worsening in disease activity by MRI, EDSS, NEDA-3/NEDA-4, fatigue questionnaire, relapse rate, walking tests, MSFC score, or attenuation of brain volume loss) OR patient experienced stabilization, slowed progression, or improvement in at least one symptom such as motor function, fatigue, vision, bowel/bladder function, spasticity, walking/gait, or pain/numbness/tingling sensation
• Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis

Approval duration

1 year